Published in Neuropsychopharmacology on October 13, 2010
Inflammation subverts hippocampal synaptic plasticity in experimental multiple sclerosis. PLoS One (2013) 0.93
Biomarkers in Multiple Sclerosis: An Up-to-Date Overview. Mult Scler Int (2013) 0.93
Neural Plasticity in Multiple Sclerosis: The Functional and Molecular Background. Neural Plast (2015) 0.91
Synaptic plasticity in multiple sclerosis and in experimental autoimmune encephalomyelitis. Philos Trans R Soc Lond B Biol Sci (2013) 0.87
Early treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity deficits in multiple sclerosis. Funct Neurol (2013) 0.85
Opposite roles of NMDA receptors in relapsing and primary progressive multiple sclerosis. PLoS One (2013) 0.81
Cognitive changes and quality of life in neurocysticercosis: a longitudinal study. PLoS Negl Trop Dis (2012) 0.80
Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis. Mult Scler Int (2011) 0.79
Ocular motor signatures of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol (2015) 0.77
Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging. Front Neurol (2016) 0.77
Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy. Ups J Med Sci (2012) 0.76
Ex vivo (18)O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway. Mol Neurodegener (2017) 0.75
The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence. Hum Brain Mapp (2016) 0.75
A synaptic model of memory: long-term potentiation in the hippocampus. Nature (1993) 29.13
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Corticocortical inhibition in human motor cortex. J Physiol (1993) 8.92
Theta burst stimulation of the human motor cortex. Neuron (2005) 8.33
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol (1999) 7.16
Synaptic AMPA receptor plasticity and behavior. Neuron (2009) 5.58
Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res (2008) 5.29
The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol (1996) 4.39
Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci (2008) 3.90
Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci (2006) 3.85
Cognitive impairment in multiple sclerosis. Lancet Neurol (2008) 3.77
Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med (2005) 3.28
TrkB signalling pathways in LTP and learning. Nat Rev Neurosci (2009) 3.12
Plasticity in the human central nervous system. Brain (2006) 2.92
Synaptic mechanisms for plasticity in neocortex. Annu Rev Neurosci (2009) 2.89
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Human motor evoked responses to paired transcranial magnetic stimuli. Electroencephalogr Clin Neurophysiol (1992) 2.27
Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol (2009) 2.20
Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain (2008) 2.18
MRI of the corpus callosum in multiple sclerosis: association with disability. Mult Scler (2010) 2.13
Techniques and mechanisms of action of transcranial stimulation of the human motor cortex. J Neurosci Methods (1997) 2.12
Selective gating of glutamatergic inputs to excitatory neurons of amygdala by presynaptic GABAb receptor. Neuron (2009) 1.85
Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci (2009) 1.83
A comprehensive review of the Paced Auditory Serial Addition Test (PASAT). Arch Clin Neuropsychol (2005) 1.81
The Rao's Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. Mult Scler (2006) 1.71
Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp Neurol (2002) 1.54
Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation (2006) 1.47
The physiological basis of the effects of intermittent theta burst stimulation of the human motor cortex. J Physiol (2008) 1.46
Mechanisms of intracortical I-wave facilitation elicited with paired-pulse magnetic stimulation in humans. J Physiol (2002) 1.36
Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology (2004) 1.36
Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol (2010) 1.34
The long-term potential of LTP. Nat Rev Neurosci (2003) 1.33
Widespread cortical thinning characterizes patients with MS with mild cognitive impairment. Neurology (2010) 1.21
Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. Neurology (2008) 1.19
Pharmacological control of facilitatory I-wave interaction in the human motor cortex. A paired transcranial magnetic stimulation study. Electroencephalogr Clin Neurophysiol (1998) 1.18
IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia. J Immunol (2008) 1.16
Cognitive changes in multiple sclerosis. Expert Rev Neurother (2008) 1.14
Interferon gamma stimulates beta-secretase expression and sAPPbeta production in astrocytes. Biochem Biophys Res Commun (2003) 1.13
Aspects of beta-amyloid as a biomarker for Alzheimer's disease. Biomark Med (2007) 1.13
Cortical plasticity in Alzheimer's disease in humans and rodents. Biol Psychiatry (2007) 1.07
Neuropsychological deficits in multiple sclerosis after acute relapse. J Neurol Neurosurg Psychiatry (1998) 1.04
The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain (2007) 1.01
Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo. Brain (2008) 1.00
TMS induced plasticity in human cortex. Rev Neurosci (2004) 1.00
GABA transporter-1 activity modulates hippocampal theta oscillation and theta burst stimulation-induced long-term potentiation. J Neurosci (2009) 0.99
Motor cortex excitability and fatigue in multiple sclerosis: a transcranial magnetic stimulation study. Mult Scler (2005) 0.99
Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol (2006) 0.99
Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid. Neurodegener Dis (2009) 0.97
Multiple sclerosis with predominant, severe cognitive impairment. Arch Neurol (2009) 0.97
Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease. Arch Neurol (2009) 0.96
A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp Neurol (2008) 0.96
BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J Alzheimers Dis (2010) 0.95
Oral treatment with a gamma-secretase inhibitor improves long-term potentiation in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther (2010) 0.92
Brain excitability changes in the relapsing and remitting phases of multiple sclerosis: a study with transcranial magnetic stimulation. Clin Neurophysiol (2004) 0.91
Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Mult Scler (2009) 0.91
Improved learning and memory in aged mice deficient in amyloid beta-degrading neutral endopeptidase. PLoS One (2009) 0.91
Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible Abeta1-42 aggregation? Exp Neurol (2009) 0.89
Intracortical excitability in patients with relapsing-remitting and secondary progressive multiple sclerosis. J Neurol (2009) 0.88
Interleukin-1beta-induced brain injury in the neonatal rat can be ameliorated by alpha-phenyl-n-tert-butyl-nitrone. Exp Neurol (2009) 0.87
Rapid-onset central motor plasticity in multiple sclerosis. Neurology (2010) 0.87
Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis. Neurology (2009) 0.85
Long-term potentiation-like facilitation through GABAA receptor blockade in the mouse dentate gyrus in vivo. Neuroreport (2008) 0.85
Cognition in multiple sclerosis: a review of neuropsychological and fMRI research. Front Biosci (Landmark Ed) (2009) 0.85
Altered response to rTMS in patients with Alzheimer's disease. Clin Neurophysiol (2005) 0.85
Cognitive decline in multiple sclerosis: impact of topographic lesion distribution on differential cognitive deficit patterns. Mult Scler (2009) 0.81
[Anxiety and cognition disorders]. Encephale (1998) 0.81
Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood (2007) 6.03
Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron (2005) 3.30
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci (2003) 3.25
A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. J Physiol (2008) 3.00
Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci (2008) 2.87
An isochore map of human chromosomes. Genome Res (2006) 2.36
Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci (2007) 2.19
Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J (2009) 1.95
MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle (2011) 1.89
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc Natl Acad Sci U S A (2004) 1.79
Cytosine methylation and CpG, TpG (CpA) and TpA frequencies. Gene (2004) 1.78
Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J Neurosci (2003) 1.66
A substrate trapping mutant form of striatal-enriched protein tyrosine phosphatase prevents amphetamine-induced stereotypies and long-term potentiation in the striatum. Biol Psychiatry (2008) 1.63
Genomic GC level, optimal growth temperature, and genome size in prokaryotes. Biochem Biophys Res Commun (2006) 1.61
Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease. Eur J Neurosci (2009) 1.59
Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci (2009) 1.59
Temporal changes of under-reporting of cigarette consumption in population-based studies. Tob Control (2010) 1.58
Interleukin-1β alters glutamate transmission at purkinje cell synapses in a mouse model of multiple sclerosis. J Neurosci (2013) 1.56
Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm (2008) 1.55
Interleukin-1β causes anxiety by interacting with the endocannabinoid system. J Neurosci (2012) 1.55
Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. J Leukoc Biol (2003) 1.55
Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? CNS Neurosci Ther (2010) 1.55
TNF-α-mediated anxiety in a mouse model of multiple sclerosis. Exp Neurol (2012) 1.55
Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease. PLoS One (2013) 1.50
Determination of κFLC and κ Index in cerebrospinal fluid: a valid alternative to assess intrathecal immunoglobulin synthesis. J Neuroimmunol (2013) 1.49
Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biol Psychiatry (2007) 1.48
Correlations between genomic GC levels and optimal growth temperatures in prokaryotes. FEBS Lett (2004) 1.48
Cortical plasticity predicts recovery from relapse in multiple sclerosis. Mult Scler (2013) 1.47
SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain (2010) 1.45
Loss of striatal cannabinoid CB1 receptor function in attention-deficit / hyperactivity disorder mice with point-mutation of the dopamine transporter. Eur J Neurosci (2011) 1.45
Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. Clin Chem Lab Med (2003) 1.43
Role of the cerebellum in externally paced rhythmic finger movements. J Neurophysiol (2007) 1.42
Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci (2003) 1.41
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci (2002) 1.40
Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology (2012) 1.40
Intra-arterial thrombectomy versus standard intravenous thrombolysis in patients with anterior circulation stroke caused by intracranial arterial occlusions: a single-center experience. J Stroke Cerebrovasc Dis (2013) 1.39
The dopamine-containing neuron: maestro or simple musician in the orchestra of addiction? Trends Pharmacol Sci (2003) 1.39
The evolution of isochore patterns in vertebrate genomes. BMC Genomics (2009) 1.38
Delayed postpartum hemorrhage: the implications of making a diagnostic mistake. Arch Gynecol Obstet (2012) 1.38
Dopamine excites fast-spiking interneurons in the striatum. J Neurophysiol (2002) 1.36
Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One (2010) 1.36
Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. Brain (2009) 1.35
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci (2006) 1.34
The GTP-binding protein Rhes modulates dopamine signalling in striatal medium spiny neurons. Mol Cell Neurosci (2007) 1.33
Mutations in the ER-shaping protein reticulon 2 cause the axon-degenerative disorder hereditary spastic paraplegia type 12. J Clin Invest (2012) 1.32
Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci (2003) 1.31
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol (2015) 1.28
Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci (2009) 1.27
FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood (2004) 1.27
Changes in intracortical circuits of the human motor cortex following theta burst stimulation of the lateral cerebellum. Clin Neurophysiol (2008) 1.27
Localization of the gene-richest and the gene-poorest isochores in the interphase nuclei of mammals and birds. Gene (2002) 1.27
Perceiving numbers alters time perception. Neurosci Lett (2008) 1.26
Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. Ann Neurol (2003) 1.26
Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov Disord (2005) 1.26
The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci (2007) 1.23
Identification and enrichment of spermatogonial stem cells displaying side-population phenotype in immature mouse testis. FASEB J (2003) 1.22
Replication timing, chromosomal bands, and isochores. Proc Natl Acad Sci U S A (2008) 1.22
Involvement of transient receptor potential-like channels in responses to mGluR-I activation in midbrain dopamine neurons. Eur J Neurosci (2003) 1.19
Proposed chronic cerebrospinal venous insufficiency criteria do not predict multiple sclerosis risk or severity. Ann Neurol (2011) 1.19
Effects of anodal transcranial direct current stimulation on chronic neuropathic pain in patients with multiple sclerosis. J Pain (2009) 1.18
Representing GC variation along eukaryotic chromosomes. Gene (2004) 1.18
Relativistic compression and expansion of experiential time in the left and right space. PLoS One (2008) 1.18
Increased facilitation of the primary motor cortex following 1 Hz repetitive transcranial magnetic stimulation of the contralateral cerebellum in normal humans. Neurosci Lett (2004) 1.17